Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Opportunity:

The Executive Director, Head of Real-World Analytics and Programming will develop and lead Revolution Medicines’ real-world analytics and programming capability, setting the strategy, operating model, technical standards, and priorities needed to generate rigorous, decision-ready real-world evidence across the product lifecycle.

Reporting to the VP, HEOR/RWE, this leader will partner closely with the Executive Director, Head of Epidemiology & RWD Strategy to align RWD strategy, drive methodologic excellence and optimize the use of data for internal decision making and evidence generation. The role will also collaborate across global and regional HEOR, Clinical Development, Safety, Regulatory, Medical Affairs, Market Access, Commercial Analytics & Insights, and IT to ensure RWE analyses address priority scientific, development, and business needs. Finally, it will be imperative that the ED, RWA&P collaborate strongly with the Development Biostatistics and EU Statistics groups to ensure alignment and overall quality of evidence generation activities.

This is an exceptional opportunity to contribute to the advancement of oncology by leveraging real-world analytics that shape the future of patient care.

The Executive Director will have the following strategic, technical, and leadership responsibilities:

Set and execute the enterprise strategy and multi-year roadmap for real-world analytics and programming in support of portfolio, Clinical Development, Safety, Medical Affairs, HEOR/RWE, and epidemiology priorities.
Provide leadership of the cross-functional matrix delivering Medical Affairs interventional studies.
Lead the assessment and fit-for-purpose use of RWD sources, including claims, electronic health records, registries, genomic/-omics data, and linked datasets; provide guidance on their strengths, limitations, and feasibility for answering priority scientific and business questions.
Provide scientific and operational leadership for RWE study design, protocol development, statistical analysis planning, programming, interpretation, and final reporting. Ensure delivery of evidence supporting regulatory submissions, product value, and critical development decisions, natural history studies, clinical trial design and optimization, comparative effectiveness and safety studies, healthcare resource utilization studies, post-approval safety studies, and rapid feasibility and landscape assessments.
Establish fit-for-purpose epidemiologic, biostatistical, and data-science methods that ensure scientific rigor, reproducibility, and alignment with global regulatory guidance and stakeholder expectations for non-interventional research.
Lead the development and adoption of scalable programming standards, reusable analytic assets, quality-control processes, and documentation practices across real-world analytics activities.
Partner with IT, data engineering, and other functions to define data requirements, establish data-ingestion and curation pipelines, and enable fit-for-purpose analytics environments and data-lake capabilities.
Provide thought leadership in advanced analytic approaches, including causal inference, predictive modeling, and AI/ML, and evaluate their appropriate use to improve evidence generation and decision-making.
Translate complex analyses into clear, actionable insights and recommendations for executive leadership, regulatory agencies, payers, external collaborators, and scientific audiences through reports, presentations, and publications.
Lead and contribute to governance, portfolio, feasibility-review, and multidisciplinary teams, ensuring real-world analytics inform high-value decisions at key development, regulatory, safety, and commercialization milestones.
Build and lead a high-performing, multidisciplinary team; foster a strong talent and capability-development culture.
Own functional resourcing, prioritization, and budget planning to ensure timely, high-quality delivery across the portfolio.

Required Skills, Experience and Education:

PhD, DSc, DrPH, MPH, or other relevant advanced degree in epidemiology, biostatistics, health outcomes, data science, or a related scientific discipline, with at least 15 years of progressively responsible experience in real-world analytics, programming, and evidence generation within pharmaceutical or biotechnology organizations.
Demonstrated success leading complex RWD/RWE programs from strategy through execution, including study design, analysis, programming, reporting, and regulatory submission support.
Demonstrated experience building, scaling, or transforming real-world analytics, programming, or data-science capabilities, including establishment of standards, processes, and cross-functional partnerships.
Strong expertise with RWD sources, including claims, EHR, registries, -omics data, and linked datasets, and analytic tools such as R, SAS, and Python.
Demonstrated technical knowledge of epidemiologic, biostatistical, and data-science methods.
Knowledge of drug and clinical development processes for genomic/targeted medicines.
Excellent analytic and problem-solving skills.
Exceptional leadership, communication, and influence skills, with the ability to work effectively across a complex matrix and shape senior-level decisions.

Preferred Skills:

Experience in oncology real-world analytics and programming.
Track record of publications or presentations in real-world analytics and programming, epidemiology, or data science.
Experience aligning RWE strategy to regulatory and payer evidence planning, especially around the planning and execution of post-approval safety studies.
Experience engaging with global regulatory authorities and interpreting evolving guidance relevant to RWD and RWE.
Demonstrated experience applying advanced analytic techniques, including causal inference, predictive modeling, and/or AI/ML, in a life-sciences evidence-generation setting.

#LI-VN1 #LI-Remote

The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.

Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.

Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.

Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].

Base Pay Salary Range

$252,000—$315,000 USD

We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.

Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.

If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.

Base Pay Salary Range 252000 - 315000 USD

About the company

Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Revolution Medicines

See people who can refer or advise you

Simplify's Take

What believers are saying

FDA approved RASONQUE on August 26, 2026, six months ahead of deadline.
RASolute 302 cut death risk 60% and doubled median overall survival to 13.2 months.
Royalty Pharma's June 2025 $2 billion package funds commercialization and global expansion through 2027.

What critics are saying

RASONQUE costs $39,800 monthly, inviting Medicare and commercial payer restrictions in 2026.
Revenue still depends overwhelmingly on one launch; any RASONQUE setback crushes the company.
AstraZeneca, Amgen, and Mirati pressure RAS programs; resistance or safety issues can erase the franchise.

What makes Revolution Medicines unique

RASONQUE became the first approved broad RAS(ON) inhibitor on August 26, 2026.
Revolution Medicines avoids companion diagnostics and treats metastatic PDAC with or without RAS mutations.
Its pipeline spans daraxonrasib, elironrasib, and zoldonrasib across pancreatic, lung, and colorectal cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%

Asianet News

Oct 16th, 2026

VSTM stock clocks best day in 11 months after positive cancer drug trial update and multiple price-target hikes.

VSTM stock clocks best day in 11 months after positive cancer drug trial update and multiple price-target hikes. Published: Oct 16 2026, 03:00 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us * Alliance Global on Thursday raised its price target on VSTM to $22 from $18 and maintained a Buy rating. * RBC Capital analyst Leonid Timashev said that while VS-7375 tolerability is not as favorable as Revolution Medicines' experimental drug Zoldonrasib, the overall profile remains acceptable. * BTIG said VS-7375 could rival Revolution Medicines' approved drug Daraxonrasib in second-line metastatic pancreatic disease. Shares of Verastem Oncology (VSTM) jumped 20% on Thursday, clocking its best day since Nov. 2025, as analysts lifted price targets following a positive update on the company's experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma. On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose, along with responses in lung and colorectal cancers and a manageable safety profile dominated by low-grade gastrointestinal side effects. Verastem also added that the company has aligned with the U.S. Food and Drug Administration on a late-stage path in first-line metastatic pancreatic cancer using chemotherapy-free regimens, with the study expected to open by year-end. Wall street weighs in on VSTM. Alliance Global on Thursday subsequently raised its price target to $22 from $18 and maintained a Buy rating, describing the updated TARGET-D 101 data as showing a highly tolerable safety profile and efficacy that is in line with or better than other drugs in the same class and in development, potentially best-in-class. RBC Capital analyst Leonid Timashev increased the target to $19 from $14 while keeping an Outperform rating, calling the drug clearly active with hints of best-in-class efficacy in pancreatic ductal adenocarcinoma. He noted that while tolerability is not as favorable as one competitor, Revolution Medicines' experimental drug Zoldonrasib, the overall profile remains acceptable. BTIG raised its target to $24 from $18 and kept a Buy rating, saying the detailed update across second-line pancreatic cancer, second-line non-small cell lung cancer, and third-line colorectal cancer points to class-leading efficacy that could rival Revolution Medicines' approved drug Daraxonrasib in second-line metastatic pancreatic disease. Jefferies analyst Faisal Khurshid raised the price target to $13 from $11 and maintained a Buy rating. Aligning on a favorable late-stage trial path, he added, positions Verastem only about seven months behind competitors Revolution Medicines and Incyte in the race to develop drugs within the same class. CEO change and Capital raising. Verastem on Wednesday also priced a $250 million offering of common stock and pre-funded warrants at $8 per share to support VS-7375 development and general purposes, expected to close around October 15. The company further announced a planned CEO transition, with longtime executive Daniel Paterson retiring effective January 1, 2027, and board member Michael P. Bailey succeeding him. How did VSTM retail traders react? On Stocktwits, retail sentiment around VSTM stayed within 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels. "The more I watch it, the more constructive it looks," a Stocktwits user wrote about the stock. View this Stocktwits post Another user drew a parallel between VSTM's current rally and Iovance Biotherapeutics Inc (IOVA) stock's rally last month, which lasted for several days. View this Stocktwits post VSTM stock has gained 2o% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

pharmaphorum

Oct 16th, 2026

RevMed nears EU okay for pancreatic cancer drug Rasonque.

RevMed nears EU okay for pancreatic cancer drug Rasonque. Revolution Medicines is likely just weeks away from getting EU approval for its oral RAS inhibitor Rasonque as a treatment for pancreatic cancer, after the drug was recommended by the EMA's human medicines committee. The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one previous treatment - the same indication that was cleared by the US FDA in August. The positive opinion is based on phase 3 results with Rasonque from the RASolute 302 trial that caused a stir at this year's ASCO cancer congress, with a doubling in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy and big improvements in quality-of-life scores. The outcome was remarkable, particularly as metastatic pancreatic adenocarcinoma is a notoriously difficult-to-treat cancer with a low survival rate. "People with metastatic pancreatic adenocarcinoma whose disease has worsened after prior treatment have limited treatment options and a poor prognosis," said the EMA, which granted Rasonque an expedited, phased review - which cut its assessment time from 210 days to less than 150 days - as a high-priority medicine that could address this unmet medical need. "Given the seriousness of the disease, [and] the limited efficacy and substantial toxicity of standard-of-care chemotherapy, there is a need for better treatment options for these patients." The RAS protein is a key driver for many tumour types, including the majority of pancreatic cancers. For many years, it was considered an 'undruggable' target, until RevMed solved the problem with daraxonrasib, constructed by binding RAS to a protein called cyclophilin A to form a complex that can attach to the RAS protein and block its activity. The pan-RAS category is pretty crowded, with more than a dozen drug candidates in clinical testing, but Revolution seems to have a healthy first-mover advantage with other trials underway in pancreatic adenocarcinoma, as well as non-small cell lung cancer (NSCLC). Those include the RASolute 303 trial in first-line pancreatic cancer, RASolute 304 in adjuvant treatment of tumours treatable with surgery, and RASolve 301 looking at first-, second-, and third-line treatment of metastatic NSCLC. There has been some noise about Rasonque's slightly lower tumour response rate in patients with KRAS G12D mutations in RASolute 302, which analysts have suggested could open the door to competition from selective drugs like Verastem Oncology's VS-7375, which is in phase 3 for pancreatic cancer. RevMed is, however, also developing a KRAS G12D-selective inhibitor, zoldonrasib, both as a monotherapy and in combination with Rasonque. 16 October, 2026

Yahoo Finance

Oct 15th, 2026

Revolution Medicines and Oruka double in 2026, beating Magnificent Seven; analysts see up to 95% upside

Two biotech stocks, Revolution Medicines and Oruka Therapeutics, have more than doubled this year, beating most of the Magnificent Seven tech group. Wall Street's average price targets suggest further gains. Revolution Medicines won approval for Rasonque, a treatment for certain patients with metastatic pancreatic cancer. In a Phase 3 study, patients lived a median 13.2 months, against 6.7 months on chemotherapy. Its market cap is about $41 billion, and its average price target of $259.14 implies 35.7% upside. Oruka Therapeutics has no approved drug. Its psoriasis candidate, ORKA-001, could be dosed once or twice a year, and has shown strong results in a Phase 2a study. The average price target of $155 implies 95% upside, but the drug has not entered Phase 3 trials.

Yahoo Finance

Oct 15th, 2026

EU regulator backs Revolution Medicines' RASONQUE for pancreatic cancer after 60% lower death risk

Revolution Medicines (Nasdaq: RVMD) said the European Medicines Agency's Committee for Medicinal Products for Human Use has backed RASONQUE (daraxonrasib), an oral tablet for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy. If the European Commission approves it, RASONQUE would be the first broad RAS-targeted treatment option in the European Union for these patients. The opinion followed an expedited review under the agency's Cancer Medicines Pathfinder project. In the Phase 3 RASolute 302 trial, the drug cut the risk of death by 60% compared with chemotherapy. Median overall survival was 13.2 months, against 6.7 months for chemotherapy. The US Food and Drug Administration approved the drug on August 26, 2026.

PR Newswire

Oct 14th, 2026

Cancer drug spending to top $400B by 2028 as RAS-targeted therapies reach pancreatic, colorectal cancers

Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute. The US accounts for roughly 46% of the total. On August 26, the US Food and Drug Administration (FDA) approved Revolution Medicines' RASONQUE (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic cancer. In a Phase 3 trial, median overall survival was 13.2 months, against 6.7 months with chemotherapy. Colorectal cancer is also drawing attention. Oncolytics Biotech expects interim data from Part A of its REO 033 study of pelareorep by year-end. Exelixis saw the FDA extend its review of zanzalintinib for metastatic colorectal cancer to March 3, 2027.

Revolution Medicines

Executive Director - Head of Real-World Analytics and Programming

About the job